Related Experiment Video
Updated: Sep 13, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Respiratory Syncytial Virus Vaccine Induced Thrombotic Microangiopathy
Robert Seby1, Benjamin J McCormick1, Emily Wolf2
1Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.
Abstract:
Microangiopathic hemolytic anemia with associated multiorgan failure is a medical emergency. The differential diagnosis for microangiopathic hemolytic anemia is broad and requires a systematic, focused approach at ruling out serious causes. However, with the rise of new vaccines and sporadic reports of vaccine-induced microangiopathic hemolytic anemia, it is essential for providers to include vaccines as a potential cause on their differential diagnosis. Here, we report the first case of respiratory syncytial virus vaccine-induced microangiopathic hemolytic anemia, anuric renal failure, and metabolic encephalopathy in the world.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Myocarditis III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Rh Blood Group

